Corporate Overview

22nd Century Group, Inc. is a leading plant biotechnology company focused on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp/cannabis plants through genetic engineering, gene-editing, and modern plant breeding. Our primary mission in tobacco is to reduce the harm caused by smoking by bringing our reduced nicotine content tobacco cigarettes – containing 95% less nicotine than conventional cigarettes – to adult smokers in the U.S. and international markets. Our mission in hemp/cannabis is to develop and commercialize proprietary hemp/cannabis plants with valuable cannabinoid profiles and desirable agronomic traits.

Why Invest

Commercializing disruptive products utilizing advanced alkaloid plant technologies to improve health

VLN® 95% reduced nicotine content cigarettes are the world’s first and only combustible cigarettes to receive Modified Risk Tobacco Product (MRTP) authorization from the FDA

North America’s largest CDMO provider of hemp-derived active ingredients for the pharmaceutical and consumer goods industries

Scaling revenue in two growth business units to achieve cash positive operations

Latest News

View all news

Latest Presentation

Latest Events

View All Events

Latest Quarterly Reports

View All Financial Reports